List view / Grid view
25 March 2015 | By Victoria White
AstraZeneca to collaborate with the HSCI to adapt a technique that creates human beta cells from stem cells to search for new treatments for diabetes...
25 March 2015 | By Victoria White
Cancer Research UK has partnered with the EPSRC to co-fund multidisciplinary research projects with up to £37.5m in funding available over five years...
24 March 2015 | By Victoria White
Semma, a company developing cell therapy for T1D, announces that it has closed a $44 million Series A consisting of equity financing and strategic funding...
24 March 2015 | By Victoria White
Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system...
24 March 2015 | By Victoria White
Rigontec, a company developing RNA-based immunotherapeutics, today announces it has raised €4.8 million in a second closing of its Series A financing round...
23 March 2015 | By Victoria White
A blood test that measures the number of prostate tumour cells shed into the bloodstream can act as an early warning sign that treatment is not working...
23 March 2015 | By Victoria White
Confluence and AOP have signed an agreement to co-develop and market a product for the treatment of Fragile X Syndrome in Europe and the Middle East...
20 March 2015 | By Victoria White
ExpreS2ion Biotechnologies announce the release by its partners at University of Copenhagen of a vaccine against placental malaria for testing in humans...
20 March 2015 | By Victoria White
Probiodrug has announced that the company will present data on its specific pGlu-Abeta mouse antibody 17/1 at AD/PDTM 2015 in Nice, France...
20 March 2015 | By Victoria White
Prothena has announced positive results from a study of PRX002, a monoclonal antibody for the potential treatment of Parkinson's disease...
19 March 2015 | By Victoria White
Alizé Pharma III SAS, a company specialised in the development of biopharmaceutical products, has raised €1.8 million in a first financing round...
19 March 2015 | By Victoria White
While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted therapies is on the rise...
19 March 2015 | By Victoria White
MISSION Therapeutics announces the appointment of Paul Wallace PhD as Chief Business Officer...
19 March 2015 | By Victoria White
PARP inhibitors that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
